Advances in sickle cell disease treatment: From drug discovery until the patient monitoring

dc.contributorUniversidade Estadual Paulista (Unesp)
dc.contributorUniversidade Estadual de Campinas (UNICAMP)
dc.date.accessioned2014-05-27T11:25:50Z
dc.date.accessioned2022-10-05T18:26:19Z
dc.date.available2014-05-27T11:25:50Z
dc.date.available2022-10-05T18:26:19Z
dc.date.created2014-05-27T11:25:50Z
dc.date.issued2011-04-01
dc.identifierCardiovascular and Hematological Agents in Medicinal Chemistry, v. 9, n. 2, p. 113-127, 2011.
dc.identifier1871-5257
dc.identifier1875-6182
dc.identifierhttp://hdl.handle.net/11449/72360
dc.identifier10.2174/187152511796196506
dc.identifier2-s2.0-79957964590
dc.identifier9734333607975413
dc.identifier0000-0003-4141-0455
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3921428
dc.description.abstractSickle Cell Disease (SCD) is one of the most prevalent hematological diseases in the world. Despite the immense progress in molecular knowledge about SCD in last years few therapeutical sources are currently available. Nowadays the treatment is performed mainly with drugs such as hydroxyurea or other fetal hemoglobin inducers and chelating agents. This review summarizes current knowledge about the treatment and the advancements in drug design in order to discover more effective and safe drugs. Patient monitoring methods in SCD are also discussed. © 2011 Bentham Science Publishers Ltd.
dc.languageeng
dc.relationCardiovascular and Hematological Agents in Medicinal Chemistry
dc.relation0,336
dc.rightsAcesso restrito
dc.sourceScopus
dc.subjectChelating agents
dc.subjectDrug discovery
dc.subjectFetal hemoglobin
dc.subjectGardos channel
dc.subjectGene therapy
dc.subjectHemoglobin modifiers
dc.subjectHydroxyurea
dc.subjectNew drugs
dc.subjectNitric oxide
dc.subjectPatient monitoring
dc.subjectPoloxamer 188
dc.subjectSickle cell
dc.subjectSickle cell treatment
dc.subjectStem cell transplant
dc.subject5 aza 2' deoxycytidine
dc.subject5 hydroxymethylfurfural
dc.subjectaldehyde derivative
dc.subjectantifungal agent
dc.subjectantiinfective agent
dc.subjectarginase
dc.subjectcalcium
dc.subjectciklavit
dc.subjectclotrimazole
dc.subjectdeferasirox
dc.subjectdeferoxamine
dc.subjectdeferoxamine mesylate
dc.subjectendothelial nitric oxide synthase
dc.subjectglutamic acid
dc.subjecthemoglobin
dc.subjecthemoglobin S
dc.subjecthydroxyurea
dc.subjectiron chelating agent
dc.subjectNiprisan
dc.subjectnitric oxide
dc.subjectns 1652
dc.subjectns 3623
dc.subjectopiate
dc.subjectorphan drug
dc.subjectplant medicinal product
dc.subjectpoloxamer
dc.subjectpyrimidine antagonist
dc.subjectunclassified drug
dc.subjectunindexed drug
dc.subjectvaline
dc.subjectvanillin
dc.subjectvitamin D
dc.subjectabsence of side effects
dc.subjectacute chest syndrome
dc.subjectacute toxicity
dc.subjectaplastic crisis
dc.subjectbioavailability
dc.subjectblood transfusion
dc.subjectbone density
dc.subjectbone marrow suppression
dc.subjectcancer development
dc.subjectcell cycle G1 phase
dc.subjectcell cycle S phase
dc.subjectdeoxygenation
dc.subjectdrug bioavailability
dc.subjectdrug cost
dc.subjectdrug design
dc.subjectdrug dose increase
dc.subjectdrug marketing
dc.subjectdrug megadose
dc.subjectdrug safety
dc.subjectenergy metabolism
dc.subjecterythrocyte shape
dc.subjecterythrocyte structure
dc.subjecterythrocyte transfusion
dc.subjectgastrointestinal symptom
dc.subjectgrowth retardation
dc.subjecthealth education
dc.subjecthemolysis
dc.subjecthuman
dc.subjecthyperpigmentation
dc.subjectimmunization
dc.subjectin vitro study
dc.subjectin vivo study
dc.subjectinfection sensitivity
dc.subjectinflammation
dc.subjectinjection site infection
dc.subjectinjection site inflammation
dc.subjectiron overload
dc.subjectleg ulcer
dc.subjectmedicinal plant
dc.subjectmulticenter study (topic)
dc.subjectneglected disease
dc.subjectosteomalacia
dc.subjectosteoporosis
dc.subjectoxygen transport
dc.subjectoxygenation
dc.subjectpain
dc.subjectpatient compliance
dc.subjectpatient monitoring
dc.subjectphase 2 clinical trial (topic)
dc.subjectplant seed
dc.subjectpriapism
dc.subjectquality of life
dc.subjectrandomized controlled trial (topic)
dc.subjectrash
dc.subjectshunting
dc.subjectsickle cell anemia
dc.subjectside effect
dc.subjectsupplementation
dc.subjectsurvival
dc.subjecttreatment duration
dc.subjectulcerative lesion
dc.subjectvitamin supplementation
dc.subjectAnemia, Sickle Cell
dc.subjectAnimals
dc.subjectAntisickling Agents
dc.subjectChelating Agents
dc.subjectDrug Discovery
dc.subjectErythrocytes
dc.subjectHemoglobins
dc.subjectHemorheology
dc.subjectHumans
dc.subjectNitric Oxide
dc.subjectPlant Preparations
dc.titleAdvances in sickle cell disease treatment: From drug discovery until the patient monitoring
dc.typeArtigo


Este ítem pertenece a la siguiente institución